Class 2

Class 2 Medicines Recall: Class 2 Medicines Recall: Aventis Pharma Limited (t/a Sanofi), Stemetil 5mg/5ml Syrup, EL(22)A/41

Sanofi is recalling all batches of Stemetil 5mg/5ml Syrup as a precautionary measure due to the identification of N-nitrosomethylphenylamine (NMPA) above the acceptable limit.

Batch Number Expiry Date Pack Size First Distributed
0032 Feb 2023 100ml 17th Sep 2020
0033 Aug 2023 100ml 26th May 2021
0034 Sep 2024 100ml 14th Dec 2021
0035 Feb 2025 100ml 04th May 2022

Active Pharmaceutical Ingredient: Prochlorperazine mesilate

Brief description of the problem

Sanofi is recalling all batches of the above product as a precautionary measure due to the identification of N-nitrosomethylphenylamine (NMPA) above the acceptable limit. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time.

Advice for healthcare professionals

Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

Healthcare professionals should advise patients undergoing treatment not to discontinue Stemetil Syrup without consulting with their prescriber. If this medicine was abruptly withdrawn, there is a possibility of the return of symptoms for which Stemetil Syrup was prescribed, and more rarely, withdrawal reactions such as nausea, vomiting, insomnia and movement disorders.

Based on the available data, there is no immediate risk to patients who have been taking this medication. Patients should be advised to discuss any questions or concerns with their prescribing healthcare professional.

Advice for patients

  • Stemetil Syrup should not be stopped without talking to your prescriber. Based on current evidence, there is no immediate risk to patients who have been taking this medication.
  • However, the Marketing Authorisation Holder will be stopping further supply of Stemetil Syrup following laboratory test results demonstrating excess levels of a chemical impurity that may potentially increase the risk of cancers if taken for a long time.
  • Your prescriber should review your treatment and consider switching to a suitable alternative going forward.

Company contacts and further information

For more information or medical information please contact: uk-medicalinformation@sanofi.com

Phone number: 0800 035 25 25

For full information: https://assets.publishing.service.gov.uk/media/633d6ff18fa8f52a5e20 4713/EL_22_A41.pdf